Ventas, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $VTR in the last 30 days.
See all $VTR insider activity →Welltower (WELL), Ventas (VTR), Omega (OHI), and CareTrust (CTRE) report strong Q2 2026 results, driven by senior housing demand. Welltower and Ventas saw SHOP NOI growth of 21% and 16%. Omega's dividend is covered by AFFO, but faces risks from Genesis Healthcare. CareTrust grew revenue 88% and maintains a strong balance sheet. All companies benefit from aging population trends.
Evercore ISI reduced its price target for Ventas from $101 to $100 but maintained an Outperform rating. The company's stock is currently trading at $86.69, with a 5-day change of -1.16% and a year-to-date change of +12.03%.
Ventas, Inc. (VTR), a healthcare REIT, has outperformed the State Street Real Estate Select Sector SPDR ETF (XLRE) with a 29.6% gain over the past year. VTR's Q2 2026 earnings beat expectations, with revenue of $1.7 billion and adjusted FFO of $0.97. The company has a market cap of $45.2 billion and operates 1,450 properties. Analysts have a 'Strong Buy' consensus with a mean price target of $102, suggesting a 15.7% upside.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning VTR (Ventas, Inc.). Coverage has skewed bearish: 0 bullish, 1 neutral, and 1 bearish.
Recent VTR coverage spans financial news, earnings and corporate actions.
Guidance increase may support the stock, though balance‑sheet leverage is a concern.
Analyst target cut suggests modest downside risk, may pressure the stock.
Earnings beat and raised guidance likely support upside pressure on the stock.
Guidance beat suggests upside potential for VTR shares.
Guidance beat and dividend raise improve cash flow outlook.
AlphAI scores every news story that mentions VTR with an AI model for sentiment and relevance, and aggregates insider trades from Ventas, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Welltower (WELL), Ventas (VTR), Omega (OHI), and CareTrust (CTRE) report strong Q2 2026 results, driven by senior housing demand. Welltower and Ventas saw SHOP NOI growth of 21% and 16%. Omega's dividend is covered by AFFO, but faces risks from Genesis Healthcare. CareTrust grew revenue 88% and maintains a strong balance sheet. All companies benefit from aging population trends.
3 min readEvercore ISI reduced its price target for Ventas from $101 to $100 but maintained an Outperform rating. The company's stock is currently trading at $86.69, with a 5-day change of -1.16% and a year-to-date change of +12.03%.
1 min readVentas, Inc. (VTR), a healthcare REIT, has outperformed the State Street Real Estate Select Sector SPDR ETF (XLRE) with a 29.6% gain over the past year. VTR's Q2 2026 earnings beat expectations, with revenue of $1.7 billion and adjusted FFO of $0.97. The company has a market cap of $45.2 billion and operates 1,450 properties. Analysts have a 'Strong Buy' consensus with a mean price target of $102, suggesting a 15.7% upside.
2 min readWelltower (WELL), Ventas (VTR), and Omega (OHI) are REITs benefiting from a growing demand for senior housing. Welltower reported 20.5% NOI growth, Ventas raised its investment target to $4.5B, and Omega faces tenant credit risks. The aging population is driving demand, while supply remains low.
3 min readFour REITs are positioned to benefit from the aging baby boomer population. Welltower (WELL) and Ventas (VTR) focus on senior housing, while Omega Healthcare (OHI) and CareTrust (CTRE) specialize in skilled nursing. Key metrics include occupancy rates, dividend coverage, and growth guidance. WELL and VTR show strong occupancy and FFO growth, while OHI and CTRE offer higher yields with varying risks.
3 min readVentas, Inc. (VTR) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 10, 2026, Ventas, Inc. (the “Company”) approved the appointment of Laurida Sayed as its Senior Vice President
1 min readJefferies launched healthcare REIT coverage, favoring senior housing due to demographics and limited supply. It initiated Janus Living (Buy, $36 target), Welltower (Buy, $275 target), and Ventas (Buy, $102 target) with Buy ratings, citing quality and growth. Healthpeak and Healthcare Realty Hold were rated neutral.
2 min readVentas, Inc. declared a quarterly cash dividend of $0.52 per share, payable on October 15, 2026, to shareholders of record on September 30, 2026. The company's stock has seen a 5-day change of -1.57% and a year-to-date change of +14.57%.
1 min readWelltower (WELL), Ventas (VTR), and Omega Healthcare (OHI) are REITs benefiting from a demographic wave of aging baby boomers. Welltower reported Q2 2026 revenue of $3.54B, up 40.9% YoY, and raised FFO guidance. Ventas saw 9% YoY FFO growth and shifted focus to SHOP. Omega Healthcare improved AFFO and raised its dividend. All three companies are positioned to capitalize on increased demand for senior housing and skilled nursing facilities.
3 min readMorgan Stanley's Ronald Kamdem expects senior housing REITs to continue outperforming due to aging population and high demand. Welltower (WELL) and American Healthcare REIT (AHR) are rated overweight, with price targets of $251 and implied upside, respectively. Ventas (VTR) is rated equal weight. All three REITs show strong occupancy and acquisition growth potential, with Welltower's dividend yield at 1.44%.
2 min read
